AIM ImmunoTech
Biopharmaceutical company focused on research and development of double-stranded RNA (dsRNA) TLR3 agonist immunomodulators for oncology, immune disorders and viral diseases. The lead investigational compound (rintatolimod) is under preclinical and clinical evaluation across oncology and post‑infectious indications, including expanded access programs and randomized Phase 2 studies.
Industries
Nr. of Employees
small (1-50)
Patents
Methods for improving exercise tolerance in myalgic encephalomyelitis patients
US-11813281-B2
View DetailsMethod of reducing antigenic drift or reassortment of viruses in a host animal using α interferon
US-11642396-B2
View Details
Methods for improving exercise tolerance in myalgic encephalomyelitis patients
US-11813281-B2
View DetailsMethod of reducing antigenic drift or reassortment of viruses in a host animal using α interferon
US-11642396-B2
View DetailsProducts
Investigational double-stranded RNA TLR3 agonist (rintatolimod)
Investigational dsRNA immunomodulator developed as a TLR3 agonist; under preclinical evaluation and in multiple clinical studies for oncology, antiviral and immune disorder indications.
Investigational double-stranded RNA TLR3 agonist (rintatolimod)
Investigational dsRNA immunomodulator developed as a TLR3 agonist; under preclinical evaluation and in multiple clinical studies for oncology, antiviral and immune disorder indications.
Services
Sponsorship and management of clinical studies (Phase 1–2 and planned Phase 3), expanded access programs, and investigator-initiated trials for dsRNA TLR3 agonists.
Sponsored research agreements and clinical collaborations with academic centers and pharmaceutical partners to evaluate combination regimens and expand clinical development.
Research activities using multi-organ microphysiological systems, iPSC-derived tissues and PK/PD modeling to evaluate efficacy, toxicity and interspecies differences.
Filing and management of patents for therapeutic compositions and uses across multiple jurisdictions.
Sponsorship and management of clinical studies (Phase 1–2 and planned Phase 3), expanded access programs, and investigator-initiated trials for dsRNA TLR3 agonists.
Sponsored research agreements and clinical collaborations with academic centers and pharmaceutical partners to evaluate combination regimens and expand clinical development.
Research activities using multi-organ microphysiological systems, iPSC-derived tissues and PK/PD modeling to evaluate efficacy, toxicity and interspecies differences.
Filing and management of patents for therapeutic compositions and uses across multiple jurisdictions.
Expertise Areas
- Clinical trial management
- Immunomodulator drug development (dsRNA/TLR3 agonists)
- Oncology therapeutics and combination immunotherapy
- Antiviral therapeutic development and preclinical antiviral models
Key Technologies
- Double-stranded RNA therapeutics (dsRNA)
- TLR3 agonist innate immune modulation
- Combination regimens with checkpoint inhibitors
- Chemokine-modulatory therapeutic approaches
News & Updates
Randomized Phase 2 clinical trial for locally advanced pancreatic adenocarcinoma opened its first clinical site and began patient recruitment.
Entered into agreements for a registered direct offering and concurrent private placement to raise gross proceeds of approximately $2.4 million to support manufacture of clinical drug supply, planned Phase 3 activities and working capital.
Appointment of a scientific officer with experience in building CRO operations, higher-throughput assay projects, microphysiological systems and funded translational research.
Peer-reviewed analysis describing in vivo protection and mechanism-of-action data for a dsRNA TLR3 agonist in Ebola virus disease models.
Awarded a Netherlands utility patent broadening coverage for dsRNA product compositions including rugged dsRNA for treatment or prevention-related uses.
Randomized Phase 2 clinical trial for locally advanced pancreatic adenocarcinoma opened its first clinical site and began patient recruitment.
Entered into agreements for a registered direct offering and concurrent private placement to raise gross proceeds of approximately $2.4 million to support manufacture of clinical drug supply, planned Phase 3 activities and working capital.
Appointment of a scientific officer with experience in building CRO operations, higher-throughput assay projects, microphysiological systems and funded translational research.
Peer-reviewed analysis describing in vivo protection and mechanism-of-action data for a dsRNA TLR3 agonist in Ebola virus disease models.
Awarded a Netherlands utility patent broadening coverage for dsRNA product compositions including rugged dsRNA for treatment or prevention-related uses.